ERBB2 and breast carcinoma: The NATALEE trial, presented at ASCO 2023, is an ongoing, open-label, large, randomized, multicenter, phase 3 trial investigating the use of adjuvant ribociclib with ET in stage II and III patients with HR+, HER2− breast cancer [36].